Intended for healthcare professionals

Letters Methylphenidate for moderate ADHD

Author’s reply to Timimi

BMJ 2013; 347 doi: (Published 06 November 2013) Cite this as: BMJ 2013;347:f6621
  1. Iain McClure, consultant child and adolescent psychiatrist1
  1. 1Royal Hospital for Sick Children, Edinburgh EH9 1LF, UK
  1. iain.mcclure{at}

Given the increasing costs of stimulant use,1 and the convincing argument about insufficient evidence that benefits outweigh harms in long term use for attention-deficit/hyperactivity disorder (ADHD) “of any severity,”2 3 isn’t it time that the Department of Health investigated the cost-benefit profile for such drug use? To decide on the best approach for our children, we need to balance the playing field. Government should match the considerable financial investment …

View Full Text

Log in

Log in through your institution


* For online subscription